If Pfizer drops PF-06425090, it will leave Valneva’s stalled VLA84 as the leading prospect. (Tracy Staton) The casualties in the Clostridium difficile vaccine race are starting to pile up. Having been ...
As Summit looks to chart a path forward, it remains financially buoyed by its $72.5 million contract with BARDA. (Gerd Altmann) Summit Therapeutics believes the future of its lead asset to treat C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results